Previous studies have revealed specific activations of the RET oncogene in multiple endocrine neoplasia type 2 (MEN 2) and thyroid tumors. To understand the role of the RET proto-oncogene activation in sporadic adrenal tumors, we analyzed the alterations of the RET proto-oncogene in the cysteine-rich extracellular domain (exons 6 and 10), the terminal region of the extracellular domain and transmembrane domain (exon 11) and the tyrosine kinase domain (exons 12-17) in 35 cases of adrenal tumors (including 18 Conn's syndrome, 3 Cushing's syndrome, 2 non-functional adrenocortical tumor and 12 pheochromocytomas by polymerase chain reaction-single strand conformational polymorphism and sequencing methods. One case with pheochromocytoma and one with Conn's syndrome had point mutation. We also detected the rearrangement of the RET gene by reverse transcription-polymerase chain reaction and Southern hybridization. One case with Conn's syndrome and one with Cushing's syndrome were found to harbor RET/PTC1 (RET tyrosine kinase domain rearranged with H4 gene). The above results indicate that RET protooncogene mutations and RET/PTC1 are involved in the pathogenesis of sporadic adrenal tumors. Mutations at codon 634 of the RET gene were also found in adrenal tumors. This suggests that the RET oncogene may also play a role in the tumorigenesis of adrenal tumors, and this possibility requires further investigation.
The RET gene was first identified as a proto-oncogene a decade ago on the basis of its ability to transform NIH 3T3 mouse cells in culture.
1) The transforming sequences that were initially recovered actually represented the product of a rearrangement between RET and another gene that had occurred during the transfection assay. Sequence analysis of the RET proto-oncogene proved that it is a member of the tyrosine kinase receptor gene family. 2, 3) The RET proto-oncogene has a calcium-binding cysteinerich extracellular domain along with a cadherin-like ligand binding site, a tyrosine kinase-containing intracellular domain, and a short transmembrane domain. 4, 5) Previous studies have shown that rearrangement of the RET gene in papillary thyroid carcinomas results in a protein with altered or novel tyrosine kinase function. 6, 7) The portion of the RET gene encoding the tyrosine kinase domain is juxtaposed to sequences from one of three other genes through chromosomal rearrangements. 8, 9) Two of the gene fusions result from rearrangement involving sequences on the same chromosome as RET (the PTC1 and PTC3 chimeras), and the third (PTC2) results from an interchromosomal rearrangement. [10] [11] [12] The frequency of RET rearrangements differs in different geographical areas, [13] [14] [15] [16] [17] [18] but whether the differences can be ascribed to environmental factors, or merely to sampling errors or differences in the techniques used, remains to be elucidated. In addition, point mutation of the RET proto-oncogene has so far only been found in multiple endocrine neoplasia type 2A (MEN 2A), MEN 2B, familial medullary thyroid carcinoma (FMTC), sporadic MTC, sporadic pheochromocytomas and Hirschsprung's disease. The point mutation sites are located in codons specifying cysteine residues, tyrosine kinase domains and intracellular domains. 19) According to the above studies, the RET proto-oncogene is specifically activated in endocrine tumors. Adrenal tumors are also a kind of endocrine tumor, but no study has yet indicated that RET oncogene activation occurs in adrenal tumors, except for pheochromocytoma. In general, functional adrenal tumors are small and characterized as benign, as well as being active hormone-producing tumors. Malignant functional tumors are relatively rare. 20, 21) Presentation of typical feature of uncontrollable overproduction of hormones makes for easy clinical diagnosis of functional adrenal tumor with the use of modern biochemical analysis or imaging technology. Because functional tumors can be diagnosed very easily and resected when the tumor is small in size, they can be used for studies. In contrast, non-functional adrenal tumors are hard to obtain. We were able to collect 2 cases of nonfunctional adrenal tumor as controls for our study. In order to clarify the role of the RET gene in the tumorigenesis of human adrenal tumors, we performed molecular studies in 35 adrenal tumor tissues. Our results suggest that the RET gene may be related to the development of these tumors.
MATERIALS AND METHODS
Patients and tissues Thirty-five adrenal tumors and their paired remnant normal adrenal tissues were obtained from patients who underwent surgery for adrenal lesions (Table  I) . These included 18 patients with primary aldosteronism, 3 patients with adrenal Cushing's syndrome, 12 patients with pheochromocytoma, and 2 patients with nonfunctional adrenal tumor. The diagnosis of primary aldosteronism was made on the basis of the clinical features, including hypertension, hypokalemia, suppression of the serum renin and the biochemical examination of increased aldosterone in blood. Further analysis by computer tomography proved the existence of unilateral adenoma. With regard to Cushing's syndrome, the diagnosis was made on the basis of the clinical features including obesity, hypertension, hirsutism, and facial plathora. Biochemical examination showed increased cortical secretion in blood. Computer tomographic scanning and pathologic findings confirmed the existence of adrenocortical tumor. The diagnosis of pheochromocytoma depended on the analysis of computer tomographic scans, pathological findings, and vanillylmandelic acid. All tissue samples were frozen at −80°C until analyzed. DNA extraction Genomic DNA was extracted from tissues by proteinase-K digestion and phenol-chloroform extraction according to Bline and Stanffard.
22)
Polymerase chain reaction-single strand conformational polymorphism (PCR-SSCP) analysis To search for mutations of the RET gene using PCR-SSCP analysis, 9 different sets of primers were prepared to amplify regions including all of the coding exons (exons 6, 10-17), as summarized in Table II . Oligonucleotides used as primers for PCR were synthesized based on the published RET gene sequence.
3) The reaction mixture contained 50 pmol of each primer, 2.5 units of Taq DNA polymerase (Boehringer Mannheim GmbH, Mannheim, Germany), 100 mM of each deoxy-nucleotide 5′-triphosphate (NTP), [α-32 P]deoxy-cytidine 5′-triphosphate (3000 Ci/mmol, 10 mCi/ml, New England Nuclear Research Products, Boston, MA), 1.5 mM MgCl 2 , 50 mM KCl, 10 mM Tris-HCl (pH 8.3), and gelatin at 10 µg/ml. A programmable thermal cycler (PTC-100, MJ Research, Watertown, MA) was used to perform 35 cycles of denaturation for 15 s each at 94°C and annealing for 15 s at 55°C for exons 6, 10, 12, 14-17, or at 60°C for exons 11 and 13, with an extension for an additional 30 s at 72°C. The total final extension time was 5 min at 72°C. The PCR-SSCP reactions were electrophoresed on 6% neutral polyacrylamide gels. Cloning and sequencing Sequence analysis of PCRamplified RET exons 6 and 11 was performed after subcloning the amplified fragment in pCR-Script cloning vector (Stratagene, La Jolla, CA). Dideoxynucleotide sequencing was done with a Sequenase kit (U.S. Biochemical, Cleveland, OH), using [α-
35
S]dATP (10 µCi/µl, New England Nuclear Research Products). Aliquots of the sequencing reaction mixtures were electrophoresed on 8% denaturing polyacrylamide gels. For accuracy, we collected 10 independent clones and performed bidirectional sequencing with the T3 and T7 sequencing primers. RT (reverse transcription)-PCR The total RNA was isolated using the acid-guanidine isothiocyanate-phenol-chloroform method 23) and used as a template for cDNA 
N, normal; ND, not detected; Conn, Conn's syndrome; Cushing, Cushing's syndrome; Pheo, pheochromocytoma; NFA, non-functional adrenal tumor.
synthesisusing 2 µg of total RNA in a 10 µl reaction mixture containing 10 pmol Oligo (dT)-15mer primer (Boehringer Mannheim GmbH), 10 mM dithiothreitol, 0.5 mM deoxy-NTP mix, acetylated bovine serum albumin (0.1 mg/ml), and reverse transcriptase from Moloney murine leukemia virus. Rearranged forms of the RET gene were amplified by using PCR with specific primers for RET/PTC1, RET/PTC2 and RET/PTC3 (Table III) and Taq DNA polymerase (Boehringer Mannheim GmbH). Southern analysis Purified genomic DNA was digested with the restriction enzyme HindIII, EcoRI, or BamHI for 6 h at 37°C. The digested DNA was size-fractionated on 1% agarose gel and transferred to a transfer membrane (Schleicher and Schuell, Dassel, Germany). The membrane was hybridized with a fluorescein-labeled 1 kb BamHI-BglII DNA fragment of RET gene as a probe in Express Hyb solution (Clontech Laboratories Inc., CA) for 1 h at 60°C. This probe, located between the transmembrane and tyrosine kinase domains of the RET gene, is able to detect the region within the RET gene where the rearrangement can occur. 24) After high stringency washing, the membrane was exposed to Kodak XAR autoradiographic film (Eastman Kodak, Rochester, NY) according to the standard method. 25) RESULTS PCR-SSCP One of 12 (8.3%) pheochromocytomas and 1 of 18 (5.6%) patients with primary aldosteronism showed an apparent electrophoretic mobility shift between the tumor and its paired adjacent normal tissue (Fig. 1) , implying the existence of a mutation. Such differences were detected in exon 6 (1 case) and exon 11 (2 cases). A mobility shift of the amplified exon 11 could be clearly detected in cases 6 and 29 ( Fig. 1, B and C) . In addition, a mobility shift of the amplified exon 6 was detected in case 29 (Fig. 1A ). All cases with mutation still showed a normal allelic band. In total, 2 of 35 (5.7%) cases of adrenal tumors had conformational alteration. Sequence analysis To examine the type of mutation, the exon 6 and 11 region was cloned from tumor specimens of case 6 and case 29. The sequencing data revealed a substitution from phenylalanine (TTC) to serine (TCC) at codon 393 (exon 6) in case 29 and a substitution from cysteine (TGC) to tryptophan (TGG) at codon 634 (exon 11) in cases 6 and 29 (Fig. 2) . The results of bidirectional sequencing of 10 independent clones confirmed that these sites were mutated in the adrenal tumor specimens we collected. RT-PCR To investigate whether RET gene rearrangement forms, including RET/PTC1, RET/PTC2 and RET/ PTC3, were also present in adrenal tumors, we performed RT-PCR on 20 adrenal tumor samples. These samples were collected from 12 patients with Conn's syndrome, 2 patients with Cushing's syndrome, 5 patients with pheochromocytoma and 1 patient with non-functional adrenal tumor. In all the cases studied before with RET gene rearrangement, the breakpoint of the RET gene occurred in an intronic sequence between the tyrosine-kinase and transmembrane encoding domains. This rearrangement was . The cDNA of c-raf-1 was also amplified to evaluate the quality of each RNA sample (Fig. 3) . RET/PTC2 and RET/PTC3 were not found in any of the tested samples. Southern blot analysis To confirm the presence of RET/ PTC1 in cases 16 and 19 and to rule out the possibility of errors in PCR, we performed Southern blot hybridization using a 1 kb BglII-BamHI RET specific DNA fragment as the probe. This fragment was able to detect the region within the RET gene where the rearrangement had occurred. This probe detected a 6.3 kb fragment after digestion with EcoRI, a 3.7 kb fragment after digestion with BamHI, and a 9.3 kb fragment after digestion with Fig. 1 . PCR-SSCP analysis of RET oncogene mutations in human adrenal tumors. Representative samples are shown for exon 6 (A) and exon 11 (B and C). An electrophoretic mobility shift of the bands between the tumor (T) and its paired normal tissue (N) implies a different conformation of the fragment, suggesting the presence of mutation in these exons. The PCR-SSCP analysis of exons 11 and 6 showed an apparent mobility shift in cases 6 and 29. HindIII in normal human DNA. Rearranged bands were found in cases 16 and 19 (Fig. 4) .
DISCUSSION
A number of studies have been done on the alterations of the RET gene in MEN2A and MEN2B. They have shown that 95% of the RET mutations occur in exons 10 and 11 in MEN2A, whereas more than 90% of them occur in exon 16 (codon 918) in MEN2B. 26) Recent studies have revealed that the frequency of RET gene mutation was 97% and the mutation hot spot was at codon 634 (86%) in MEN2A. 27, 28) This suggests that mutation at codon 634 is associated with the transforming ability of the RET gene. Furthermore, Santoro et al. 29) have indicated that the dimerization of the RET oncoprotein caused the activation of the RET gene in MEN2A. For the above reasons, the RET gene plays an important role in MEN2A. To understand the role of the RET gene in adrenal tumors, we examined 18 cases with Conn's syndrome, 3 cases with Cushing's syndrome, and 12 cases with pheochromocytoma. The results showed that 2 patients, one with Conn's syndrome and the other with pheochromocytoma, had RET gene mutations at codon 634, resulting in a cysteineto-tryptophan substitution. Codon 634 is located in the extracellular domain close to the transmembrane domain. Mutations of codon 634 may influence the structure of the RET protein receptor, 29) leading to loss of specificity of ligand binding or activation of the RET protein in the absence of ligand binding. Uncontrolled RET protein activation would contribute to cell malignancy. This suggests that the mutations at codon 634 of the RET gene may be involved in the development of adrenal tumors. On the other hand, one of the 2 cases showed a phenylalanine-toserine substitution at codon 393, which was also found in Hirschsprung's disease. In addition, a loss-of-function effect of missense mutation at codon 393 of the RET protein has been demonstrated. 30, 31) With regard to rearrangement of the RET oncogene, this was found in thyroid carcinomas, with most of them being RET/PTC1. RET/ PTC1 is the rearrangement between the RET gene and H4 (D10S170) gene. The chimera point is located at 1843 bp of the RET gene, flanking intron 11, which is upstream of the tyrosine kinase domain. RET/PTC1 was found in most thyroid tumors. The prevalence of RET/PTC1 varies in different geographical areas and in different ethnic populations. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Previous studies have suggested that RET/ PTC1 rearrangement may induce activation of the RET oncogene in three situations. 9) 1. When the rearrangement occurs at the N-terminus, the ligand binding sites change, so the foreign gene insertion might activate RET tyrosine kinase and cause the RET oncoprotein activation. 2. When the replaced region of the RET gene contains a transmembrane domain, the rearrangement will change the domain to a free protein in the cytoplasm, so the protein can easily be activated by other proteins. 3. When deletion of the RET protein receptor occurs, RET/PTC1 might be autophosphorylated without any ligand stimulation. These hypotheses need to be studied further to determine which is the real mechanism of RET oncogene activation. In this study, we found that RET/PTC1 was also present in adrenal tumors, indicating that rearrangement of the RET oncogene also plays a role in tumorigenesis in adrenal tumors. RET gene mutation and rearrangement were not (lanes 2, 4, 6 ), or HindIII (lanes 1, 4, 7) and hybridized to a 1.0 kb BamHI-BglII RET-specific DNA probe. Both RET proto-oncogene and the RET/PTC rearrangement band were seen in tumor tissue of cases 16 and 19, indicating that the tumors are both heterozygotic for the rearrangement.
found in many of the cases we analyzed; however, it is known that the mutation site (codon 634) and rearrangement form (RET/PTC1) are associated with the transforming activity of the RET gene. This indicates that alterations of the RET gene may contribute to adrenal tumor development. Additionally, our results show that the occurrence of the RET gene mutation and rearrangement are not associated with the tumor size, indicating that they may be initial events in adrenal tumor development. Furthermore, numerous studies have shown that the RET proto-oncogene is involved in neurodifferentiation and the nervous system is associated with the secretion of adrenocortical cells. Whether the RET gene also plays a crucial role in hormone overexpression is something we are still investigating.
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